MA39821A - Molécules de liaison spécifiques de l'il-21 et leurs utilisations - Google Patents

Molécules de liaison spécifiques de l'il-21 et leurs utilisations

Info

Publication number
MA39821A
MA39821A MA039821A MA39821A MA39821A MA 39821 A MA39821 A MA 39821A MA 039821 A MA039821 A MA 039821A MA 39821 A MA39821 A MA 39821A MA 39821 A MA39821 A MA 39821A
Authority
MA
Morocco
Prior art keywords
antibodies
binding molecules
antigen
disclosure provides
binding
Prior art date
Application number
MA039821A
Other languages
English (en)
Other versions
MA39821B1 (fr
Inventor
Laura Carter
Partha Chowdhury
Melissa Damschroder
Stacey Drabic
Qun Du
Catherine Ettinger
Ronald Herbst
Jodi Karnell
Brian Michael Naiman
Ping Tsui
Reena Varkey
Xiaodong Xiao
Original Assignee
Boston Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54288526&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA39821(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boston Pharmaceuticals Inc filed Critical Boston Pharmaceuticals Inc
Publication of MA39821A publication Critical patent/MA39821A/fr
Publication of MA39821B1 publication Critical patent/MA39821B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Materials For Medical Uses (AREA)
  • Dental Preparations (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des molécules de liaison de l'il-21, par exemple, des anticorps anti-il-21 et des fragments de liaison à l'antigène de ceux-ci. Dans certains aspects, les anticorps anti-il-21 et fragments de ceux-ci peuvent être des anticorps monoclonaux murins dérivés d'hybridomes et des versions humanisées de ceux-ci. Dans certains aspects, les molécules de liaison, par exemple, les anticorps anti-il-21 et les fragments de liaison à l'antigène de ceux-ci prévus ici inhibent, suppriment ou antagonisent l'activité de l'il -21. En outre, la présente invention concerne des compositions et des procédés pour le diagnostic et le traitement de maladies ou de troubles, par exemple, de maladies ou de troubles inflammatoires, à médiation immunitaire ou auto-immuns associés à la transduction de signal médiée par l'il-21. Dans un mode de réalisation particulier, l'invention concerne des procédés pour traiter ou prévenir une réaction de greffe contre hôte (gvhd) à l'aide de molécules de liaison de l'il-21, par exemple, d'anticorps anti-il-21 et de fragments de liaison à l'antigène de ceux-ci.
MA39821A 2014-04-08 2015-04-07 Molécules de liaison spécifiques de l'il-21 et leurs utilisations MA39821B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461976684P 2014-04-08 2014-04-08
PCT/US2015/024650 WO2015157238A2 (fr) 2014-04-08 2015-04-07 Molécules de liaison spécifiques de l'il-21 et leurs utilisations

Publications (2)

Publication Number Publication Date
MA39821A true MA39821A (fr) 2017-02-15
MA39821B1 MA39821B1 (fr) 2020-09-30

Family

ID=54288526

Family Applications (2)

Application Number Title Priority Date Filing Date
MA39821A MA39821B1 (fr) 2014-04-08 2015-04-07 Molécules de liaison spécifiques de l'il-21 et leurs utilisations
MA050678A MA50678A (fr) 2014-04-08 2015-04-07 Molécules de liaison spécifiques de l'il-21 et leurs utilisations

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA050678A MA50678A (fr) 2014-04-08 2015-04-07 Molécules de liaison spécifiques de l'il-21 et leurs utilisations

Country Status (24)

Country Link
US (4) US10022443B2 (fr)
EP (2) EP3689325A1 (fr)
KR (1) KR102546611B1 (fr)
CN (2) CN106794129B (fr)
AU (2) AU2015244025B2 (fr)
CA (2) CA2948275C (fr)
CY (1) CY1123275T1 (fr)
DK (1) DK3128997T3 (fr)
ES (1) ES2814150T3 (fr)
HR (1) HRP20201377T1 (fr)
HU (1) HUE051676T2 (fr)
IL (2) IL248709B (fr)
LT (1) LT3128997T (fr)
MA (2) MA39821B1 (fr)
PL (1) PL3128997T3 (fr)
PT (1) PT3128997T (fr)
RS (1) RS60795B1 (fr)
RU (1) RU2708336C2 (fr)
SG (2) SG10201913627TA (fr)
SI (1) SI3128997T1 (fr)
SM (1) SMT202000464T1 (fr)
TW (1) TWI665214B (fr)
WO (1) WO2015157238A2 (fr)
ZA (1) ZA201707489B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017223283A1 (fr) * 2016-06-22 2017-12-28 Icahn School Of Medicine At Mount Sinai Molécules de liaison au noyau et au mini-noyau du vhc
US20180325931A1 (en) 2017-01-21 2018-11-15 Ningbo Zhiming Biotechnology Co., Ltd. Use of paeoniflorin-6'-o-benzenesulfonate in treatment of sjögren's syndrome
ES2910969T3 (es) 2017-08-03 2022-05-17 Amgen Inc Muteínas de interleucina-21 y métodos de tratamiento
WO2019052562A1 (fr) * 2017-09-15 2019-03-21 科济生物医药（上海）有限公司 Protéine de fusion d'une il-4r et son utilisation
TW201930344A (zh) 2018-01-12 2019-08-01 美商安進公司 抗ｐｄ-１抗體及治療方法
WO2020023702A1 (fr) 2018-07-25 2020-01-30 AskGene Pharma, Inc. Nouveaux promédicaments d'il-21 et leurs procédés d'utilisation
WO2020252264A1 (fr) 2019-06-12 2020-12-17 AskGene Pharma, Inc. Nouveaux promédicaments d'il-15 et leurs procédés d'utilisation
JP2022545439A (ja) 2019-08-21 2022-10-27 アスクジーン・ファーマ・インコーポレイテッド 新規ｉｌ－２１プロドラッグおよびその使用方法
AU2020353672A1 (en) * 2019-09-25 2022-03-31 Surface Oncology, LLC Anti-IL-27 antibodies and uses thereof
CN113321729B (zh) * 2021-07-01 2022-08-30 东大生物技术(苏州)有限公司 一组il-12单克隆抗体及其医药用途
CN116554323B (zh) * 2023-04-27 2024-02-27 中南大学湘雅二医院 人源化抗il21抗体的开发和应用
WO2025257327A1 (fr) 2024-06-13 2025-12-18 Almirall, S.A. Approches thérapeutiques pour la gestion de l'hidradénite suppurée

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
DE3588239T3 (de) 1985-03-30 2007-03-08 Kauffman, Stuart A., Santa Fe Verfahren zum Erhalten von DNS, RNS, Peptiden, Polypeptiden oder Proteinen durch DMS-Rekombinant-Verfahren
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
DE3600905A1 (de) 1986-01-15 1987-07-16 Ant Nachrichtentech Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5763192A (en) 1986-11-20 1998-06-09 Ixsys, Incorporated Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2016842A1 (fr) 1989-05-16 1990-11-16 Richard A. Lerner Methode pour puiser dans le repertoire immunologique
CA2016841C (fr) 1989-05-16 1999-09-21 William D. Huse Methode de production de polymeres ayant une activite choisie
FI915411A0 (fi) 1989-05-16 1991-11-15 Scripps Research Inst Samexpression av heteromeriska receptorer.
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
EP1291360A1 (fr) 1991-12-13 2003-03-12 Xoma Corporation Procedes et matieres de preparation de domaines variables d'anticorps modifies et leurs utilisations therapeutiques
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6828422B1 (en) 1995-08-18 2004-12-07 Morphosys Ag Protein/(poly)peptide libraries
WO1997008320A1 (fr) 1995-08-18 1997-03-06 Morphosys Gesellschaft Für Proteinoptimierung Mbh Banques de proteines/(poly)peptides
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
JP2002530066A (ja) * 1998-11-19 2002-09-17 スミスクライン・ビーチャム・コーポレイション Ｒｈａｍｍアンタゴニスト抗体
WO2001002588A2 (fr) 1999-07-02 2001-01-11 Morphosys Ag Production de partenaires de liaison specifiques se liant a des (poly)peptides codes par des fragments d'adn genomiques ou est
US20040038339A1 (en) * 2000-03-24 2004-02-26 Peter Kufer Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
DK1578446T3 (en) 2002-11-07 2015-06-29 Immunogen Inc ANTI-CD33 ANTIBODIES AND PROCEDURES FOR TREATING ACUTE MYELOID LEUKEMIA BY USING IT
US20070092485A1 (en) 2002-11-15 2007-04-26 Zymogenetics, Inc. Cytokine zalpha11 ligand
CA2518371A1 (fr) 2003-03-14 2004-09-30 Wyeth Anticorps diriges contre le recepteur humain de l'il-21 et utilisations correspondantes
WO2005075514A2 (fr) 2004-03-10 2005-08-18 Lonza Ltd. Procede de production d'anticorps
WO2005113001A1 (fr) * 2004-05-20 2005-12-01 Zymogenetics, Inc. Procedes de traitement du cancer par polytherapie associant il-21 et des anticorps monoclonaux
CN101052419A (zh) * 2004-08-05 2007-10-10 惠氏公司 拮抗白介素－21受体活性
CA2574848A1 (fr) 2004-08-05 2006-12-21 Wyeth Inhibition de l'activite du recepteur d'interleukine 21
EP1685161A1 (fr) 2004-08-30 2006-08-02 Lonza Biologics plc Chromatographie d'affinite plus chromatographie par echanges d'ions pour la purification des anticorps
ITRM20040586A1 (it) * 2004-11-29 2005-02-28 Giuliani Spa Epitopi antigenici dell'interleuchina-21, anticorpi relativi e loro uso in campo medico.
EP1960433A2 (fr) 2005-11-28 2008-08-27 Zymogenetics, Inc. Antagonistes du recepteur de il-21
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
US20080267910A1 (en) 2007-03-09 2008-10-30 Wu Paul W Rat, rabbit, and cynomolgus monkey IL-21 and IL-22 nucleotide and polypeptide sequences
WO2009047360A1 (fr) * 2007-10-11 2009-04-16 Novo Nordisk A/S Anticorps il-21
EP2217268B1 (fr) * 2007-12-07 2016-05-04 ZymoGenetics, Inc. Anticorps monoclonaux anti-il-21 humain
WO2009092014A1 (fr) 2008-01-18 2009-07-23 Gagnon Peter S Purification améliorée d'anticorps et de fragments d'anticorps par chromatographie sur hydroxyapatite
US8114968B2 (en) 2008-03-03 2012-02-14 Dyax Corp. Metalloproteinase-12 specific monoclonal antibody
JP5470817B2 (ja) 2008-03-10 2014-04-16 日産自動車株式会社 電池用電極およびこれを用いた電池、並びにその製造方法
JP5593560B2 (ja) * 2008-06-30 2014-09-24 オンコセラピー・サイエンス株式会社 放射性同位体標識で標識された抗ｃｄｈ３抗体およびその使用
US8580714B2 (en) * 2009-10-14 2013-11-12 Janssen Biotech, Inc. Methods of affinity maturing antibodies
SG191716A1 (en) * 2010-11-19 2013-08-30 Toshio Imai Neutralizing anti-ccl20 antibodies
JP6136279B2 (ja) 2013-01-15 2017-05-31 株式会社ジェイテクト 転がり軸受装置
TWI503850B (zh) 2013-03-22 2015-10-11 Polytronics Technology Corp 過電流保護元件
TWI510996B (zh) 2013-10-03 2015-12-01 Acer Inc 控制觸控面板的方法以及使用該方法的可攜式電腦
AR099625A1 (es) * 2014-03-21 2016-08-03 Lilly Co Eli Anticuerpos de il-21
US9816280B1 (en) 2016-11-02 2017-11-14 Matthew Reitnauer Portable floor

Also Published As

Publication number Publication date
SMT202000464T1 (it) 2020-09-10
US20200164069A1 (en) 2020-05-28
EP3128997A2 (fr) 2017-02-15
NZ762893A (en) 2023-10-27
EP3689325A1 (fr) 2020-08-05
CN106794129B (zh) 2020-05-12
US20180318416A1 (en) 2018-11-08
WO2015157238A3 (fr) 2015-12-10
AU2019202447A1 (en) 2019-05-02
CA3208721A1 (fr) 2015-10-15
NZ725735A (en) 2023-09-29
AU2019202447B2 (en) 2020-09-10
CA2948275A1 (fr) 2015-10-15
AU2015244025B2 (en) 2019-03-21
RU2708336C2 (ru) 2019-12-05
US10022443B2 (en) 2018-07-17
KR20170018814A (ko) 2017-02-20
TWI665214B (zh) 2019-07-11
RU2016143378A3 (fr) 2019-01-21
CN111560071B (zh) 2023-09-05
US10588969B2 (en) 2020-03-17
TW201620934A (zh) 2016-06-16
US11529415B2 (en) 2022-12-20
US20170173149A1 (en) 2017-06-22
IL273641A (en) 2020-05-31
HRP20201377T1 (hr) 2021-02-19
ZA201707489B (en) 2019-06-26
SG10201913627TA (en) 2020-03-30
BR112016029734A2 (pt) 2021-11-16
EP3128997A4 (fr) 2017-12-13
CN111560071A (zh) 2020-08-21
SG11201609178SA (en) 2016-12-29
IL248709A0 (en) 2017-03-30
ES2814150T3 (es) 2021-03-26
RS60795B1 (sr) 2020-10-30
WO2015157238A2 (fr) 2015-10-15
KR102546611B1 (ko) 2023-06-22
SI3128997T1 (sl) 2020-11-30
AU2015244025A1 (en) 2016-11-17
PL3128997T3 (pl) 2020-12-28
EP3128997B1 (fr) 2020-08-05
MA39821B1 (fr) 2020-09-30
CY1123275T1 (el) 2021-12-31
HUE051676T2 (hu) 2021-03-29
MA50678A (fr) 2020-08-05
IL273641B (en) 2021-04-29
DK3128997T3 (da) 2020-08-24
PT3128997T (pt) 2020-09-04
LT3128997T (lt) 2020-10-12
RU2016143378A (ru) 2018-05-08
IL248709B (en) 2020-08-31
CA2948275C (fr) 2023-10-17
CN106794129A (zh) 2017-05-31
US20230201346A1 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
MA39821A (fr) Molécules de liaison spécifiques de l'il-21 et leurs utilisations
MX2018012757A (es) Anticuerpos agonistas que se unen a cd40 humana y usos de los mismos.
JOP20190002A1 (ar) أجسام مضادة (أنتي – بي دي – 1) وطريقة الإنتاج وطريقة استخدام كل منهم
EP4631978A3 (fr) Anticorps anti-cd3 humanisés ou chimériques
NZ748777A (en) Binding molecules specific for fcγriia and uses thereof
EA201890305A1 (ru) Гуманизированные или химерные cd3-антитела
MY208022A (en) Anti-claudin 18.2 antibody and application thereof
PH12016501366A1 (en) Novel anti-baff antibodies
MX2016005765A (es) Anticuerpos anti-il-17, un metodo para producir y utilizar los mismos.
WO2016014688A3 (fr) Anticorps anti-pd-1
MX2022010623A (es) Terapias de combinacion que comprenden un receptor quimerico de antigeno cd19 para el cancer.
PH12020552006A1 (en) Antibodies specific for cd3 and uses thereof
WO2012118813A3 (fr) Anticorps anti-récepteurs il-6 et leurs procédés d'utilisation
PH12020552235A1 (en) Anti-cd40 antibodies for use in treating autoimmune disease
PH12014500408A1 (en) Anti-alphabetatcr antibody
MX2017005987A (es) Anticuerpos anti-interleucina(il)-1beta y metodos de uso.
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
HK1255056A1 (zh) 抗cd115抗体
WO2013138244A3 (fr) Traitement de la sclérose en plaques par un anticorps anti-cd19
MX2018009264A (es) Anticuerpo de trombina, fragmento de antigeno y sus usos farmaceuticos.
MX2018004406A (es) Anticuerpo monoclonal bactericida contra la klebsiella pneumoniae.
GEP20267856B (en) Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy
HK1216754A1 (zh) 抗-rankl抗体及其使用方法
MX2017003014A (es) Anticuerpos anti-alfa v beta 5 humanizados y usos de estos.